Current Research in Emergency Medicine
[ ISSN : 2832-5699 ]

Cyproheptadine in Hospitalized Patients in the ICU for COVID-19: A Case Series

Case Series
Volume 2 - Issue 6 | Article DOI : 10.54026/CREM/1042

Alexandre Noel1*, Philippe Rola1 and Farid Jalali2

1Intensive Care Unit-Santa Cabrini Hospital, Montreal, Canada
2Memorial Care, California, USA

Corresponding Authors

Alexandre Noel, MD, Intensive Care Unit-Santa Cabrini Hospital, Montreal, Canada.


COVID-19; WHO; Cyproheptadine; Treatment; Hospitalization

Received : August 08, 2022
Published : August 25, 2022


The COVID-19 pandemic has had a terrible toll in terms of mortality and overwhelming health care systems worldwide. The race to handle the disease had precipitated research on both repurposed drugs as well as the development of new ones. There is biological plausibility for cyproheptadine to be useful as an anti-serotonergic agent. In this retrospective case series, we show that cyproheptadine has no significant side effects in a monitored setting that would preclude a larger trial to be done to assess potential therapeutic efficacy.